In a patient with nephrotic syndrome, renal biopsy revealed AL amyloid deposits. Monoclonal light chains were identified in serum and urine. A low percentage of monoclonal plasma cells was detected in the bone marrow. The patient received four cycles of VAD and subsequent high-dose chemotherapy (HDCT) with melphalan (200 mg/m 2 ) followed by autologous peripheral blood stem cell transplantation. Proteinuria rapidly diminished during chemotherapy. Three months after HDCT, the patient has no edema, and no signs of plasma cell dyscrasia are currently detectable. Using VAD before starting HDCT may improve the condition of patients with amyloidosis and reduce transplantationrelated morbidity and mortality.
Primary systemic AL (amyloid light-chain) amyloidosis is a plasma cell disorder in which depositions of amyloid light-chain protein cause progressive organ failure. 1 It is one of the most common subtypes of amyloidosis. Amyloid fibrils consist of the N-terminal region of light-chains (more often then ) derived from a monoclonal plasma cell population. Clinical manifestations are varied and depend on the amyloid deposition in different organs. The organs most commonly involved are the kidneys and heart, but any other organ apart from the brain can be affected. The prognosis of primary amyloidosis is generally poor with a median survival of 1-2 years. 2 Less than 20% of patients with amyloidosis have multiple myeloma or Waldenstrom ' High-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (PBSCT) can be performed to eradicate the plasma-cell clone producing amyloidogenic proteins. Only a few cases of primary amyloidosis have been treated with HDCT to date. 4, 5 The first patient with amyloidosis treated with HDCT died of a transplantrelated complication, 4 and another study with upfront HDCT resulted in 20% early death rate. 5 Here, we report a new approach using the VAD regimen with subsequent HDCT after achieving a remission. This approach, which resulted in an improvement of the status of the patient before HDCT, might reduce transplant-related morbidity and mortality in amyloidosis.
Case report
A 53-year-old patient with nephrotic syndrome due to primary amyloidosis was treated with HDCT and PBSCT in January 1998.
The patient noticed peripheral edema in April 1997. His previous medical history was unremarkable. Physical examination showed symmetrical edema of the legs and a moderate tachycardia. Proteinuria was 5 g/24 h. Urine analysis revealed glomerular proteinuria with traces of free monoclonal IgG-light chains. Immunofixation of the serum showed monoclonal IgG-light chains. The patient had hypoproteinemia with elevated concentrations of lipoproteins. Serum electrophoresis showed a nephrotic pattern with high ␣1-and ␣2-globulin and low albumin. IgG, IgM, IgA and ␤2-microglobulin were within the normal ranges. Creatinine was 111 mol/l, haemoglobin 119 g/l, platelets 286 × 10 9 /l and WBC 4.0 × 10 9 /l with normal differentiation.
The renal biopsy showed diffuse interstitial amyloid deposits with polarised light green birefringence after Congo red staining. Immunohistochemical staining revealed light chains of -isotype. The slightly hypocellular BM biopsy contained about 10% plasma cells. Clonal dominance of light chains (/-ratio: 6:1) was demonstrated by immunohistochemical staining. On flow cyto-metric analysis of BM aspirate, plasma cells were characterised by a strong coexpression of CD38 and positive B-B4. The majority of these cells showed an abnormal phenotype with negative CD19 and positive CD56. 6 Skeletal radiology showed no signs of osteolysis or diffuse osteopenia.
Electrocardiogram showed sinus tachycardia with 110 b.p.m. with absent R-waves and T-wave inversion in leads V4-V6. Echocardiography revealed concentric thickening of the left ventricle with a low normal ejection fraction, a mild restrictive filling pattern, an increase of the interventricular septal width to 14 mm and a small pericardial effusion, all consistent with cardiac involvement by amyloidosis. At the patient's request chemotherapy was started with conventional-dose melphalan and prednisone but the proteinuria increased further to 6 g/24 h after the first and to 9 g/24 h after the second course.
Subsequently high-dose chemotherapy with PBSCT was considered. The patient received four courses of VAD (vincristine 0.4 mg/day and doxorubicin 9 mg/m 2 /day, continuous infusion, days 1-4, dexamethasone 40 mg/day, p.o., days 1-4, 9-12, 17-20) repeated every 4 weeks. While on VAD, the creatinine remained unchanged but proteinuria improved rapidly (before first cycle 9.13 g/day, second cycle 8.19 g/day, third cycle 5.94 g/day, forth cycle 3.37 g/day, 4 weeks after fourth cycle 2.37 g/day) and peripheral edema diminished. Serum albumin level increased from 29.5 g/l before the first cycle to 38.8 g/l after the fourth cycle. BM biopsy showed mild hypocellularity with less then 5% mature plasma cells. On flow cytometric analysis of the BM aspirate, only 0.4% plasmocytes were detected, characterised by a predominantly normal phenotype with positive CD19 and negative CD56. After chemotherapy with VAD, haematopoietic stem cells were mobilised with G-CSF (480 g/day s.c. for 5 days). 5 × 10 6 /kg CD34-positive cells were collected and cryopreserved.
Five weeks after the last cycle of VAD, HDCT was performed using melphalan 200 mg/m 2 . The patient received oral antimicrobial prophylaxis with cotrimoxazol, amphotericin and colistin. Haematological recovery was supported by G-CSF (480 g/day).
HDCT and PBSCT were tolerated well apart from moderate nausea, vomiting and grade 3 mucositis according to WHO. Seven days after PBSCT, antibiotic treatment was started because of fever of unknown origin. Full haematological recovery was observed on day 9 after PBSCT and the patient was discharged on day 18. The creatinine, which had increased to a maximum of 243 mol/l after HDCT, decreased to 202 mol/l at this time.
Three months after PBSCT renal function had improved further with diminished proteinuria of 1.6 g/day and creatinine of 135 mol/l. Serum albumin increased to 43.7 g/l. Immunofixation of serum and urine showed no evidence of monoclonal light chains. BM biopsy revealed normal cellularity with less then 5% polyclonal mature plasma cells. In flow cytometric analysis of the BM aspirate a normal, low number of plasma cells was detected of normal phenotype. The ratio of intracellular light-chains was also normal (/-ratio: 2:1). There was no significant change in interventricular septal width. The patient is now in good clinical condition with no complaints.
Discussion
There is no treatment available which improves impaired organ function by induction of amyloid mobilisation. However, amyloidosis is a dynamic process, and measures which reduce the supply of the amyloid fibril precursor protein can result in a major regression of the deposits. 7 In the present case, histologically proven renal involvement resulted in nephrotic syndrome, and cardiac amyloidosis was assumed because of the echocardiographic findings. There was no evidence of myeloma. The disease symptoms progressed during treatment with melphalan and prednisolone, but with VAD a rapid improvement of the clinical features was observed. Three months after consolidation with HDCT the patient is in a good condition and has now returned to work.
Treatment of primary systemic amyloidosis with standard-dose melphalan results in low response rates and the response is slow.
3 VAD has been shown to be active in AL amyloidosis. 8, 9 Since adverse cardiac effects of anthracyclines in patients with cardiac involvement are possible, high-dose dexamethasone alone instead of VAD may be another option, but data concerning the activity of dexamethasone monotherapy are controversial in AL amyloidosis. 10, 11 HDCT can offer clinical benefit to some patients with amyloidosis 12 due to improvement of organ functions and complete remission of the plasma-cell dyscrasia. On the other hand, upfront HDCT is associated with significant mortality in amyloidosis. 4, 5 On an intention-to-treat basis, the early mortality associated with attempted HDCT was 20% in a recent publication. 5 Due to cardiopulmonary failure, even stem cell collection can be associated with a lethal outcome in amyloidosis. 5 In amyloidosis, a new approach is treatment with VADlike regimens without stem cell toxicity, before HDCT. This approach is common in the treatment of multiple myeloma. Chemotherapy with VAD may stop disease progression prior to undertaking HDCT. Furthermore, VAD resulted in rapid reduction of disease symptoms within a few months in this case. The improved status of the patient before HDCT might reduce the transplant-related morbidity and mortality in amyloidosis. During VAD therapy, parameters of disease activity should be monitored closely to enable a switch to alternative treatment forms if the response is not satisfactory.
Monoclonal plasma cells can be detected in the peripheral blood of patients with primary amyloidosis. 13 Upfront chemotherapy before peripheral stem cell harvest can reduce the number of circulating clonogenic cells and thereby the contamination of the leukapheresis product. Although allogeneic bone marrow transplantation eliminates the problem of contamination and has been shown to be feasible in selected patients with AL amyloidosis, 14 the impaired organ function may increase the risk associated with this treatment.
